Vir Biotechnology (VIR) Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
VIR Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Vir Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.30 |
| 52 Week High | US$14.45 |
| 52 Week Low | US$4.25 |
| Beta | 1.18 |
| 1 Month Change | -23.89% |
| 3 Month Change | -8.51% |
| 1 Year Change | -49.23% |
| 3 Year Change | -84.59% |
| 5 Year Change | -91.98% |
| Change since IPO | -69.33% |
Recent News & Updates
Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 09
Vir Biotechnology: Hep B And Cancer Projects March On
Jul 23Recent updates
Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Aug 09Vir Biotechnology: Hep B And Cancer Projects March On
Jul 23Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts
May 11
Strong Clinical Advances In Oncology And Hepatitis Delta Will Secure Future Success
ECLIPSE Phase III program in hepatitis delta and oncology advancements promise revenue and earnings growth through new treatments and diversified revenue streams.Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology
Mar 04Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong?
Jan 09Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Invest In Growth?
Jan 07Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January
Dec 13Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off
Nov 05Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts
Nov 04Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?
Sep 08Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results
Aug 03Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis
Jul 17Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates
May 05Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders
May 03Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
Feb 28Sticking With Vir Biotechnology
Jan 17Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%
Aug 07Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive
Jul 24Shareholder Returns
| VIR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -15.7% | -1.5% | 2.4% |
| 1Y | -49.2% | -7.7% | 20.2% |
Return vs Industry: VIR underperformed the US Biotechs industry which returned -7.7% over the past year.
Return vs Market: VIR underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| VIR volatility | |
|---|---|
| VIR Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VIR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VIR's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 408 | Marianne De Backer | www.vir.bio |
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Vir Biotechnology, Inc. Fundamentals Summary
| VIR fundamental statistics | |
|---|---|
| Market cap | US$597.34m |
| Earnings (TTM) | -US$550.23m |
| Revenue (TTM) | US$19.00m |
Is VIR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VIR income statement (TTM) | |
|---|---|
| Revenue | US$19.00m |
| Cost of Revenue | US$486.60m |
| Gross Profit | -US$467.60m |
| Other Expenses | US$82.63m |
| Earnings | -US$550.23m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.96 |
| Gross Margin | -2,461.06% |
| Net Profit Margin | -2,895.94% |
| Debt/Equity Ratio | 0% |
How did VIR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/11 21:15 |
| End of Day Share Price | 2025/08/08 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vir Biotechnology, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Huidong Wang | Barclays |
| Alec Stranahan | BofA Global Research |